How to buy Vaccinex stock | $2.3

Vaccinex, Inc is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccinex employs 45 staff and has a trailing 12-month revenue of around USD$625,000.

How to buy shares in Vaccinex

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Vaccinex. Find the stock by name or ticker symbol: VCNX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vaccinex reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vaccinex, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Vaccinex. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Vaccinex share price

Use our graph to track the performance of VCNX stocks over time.

Vaccinex shares at a glance

• Key figures

Information last updated 2020-12-02.

Latest market close	USD$2.3
52-week range	USD$1.63 - USD$9.6
50-day moving average	USD$1.9529
200-day moving average	USD$3.8249
Wall St. target price	USD$13.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.011

Buy Vaccinex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Vaccinex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vaccinex, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaccinex price performance over time

Historical closes compared with the close of $2.3 from 2020-12-09

1 week (2021-01-05)	7.98%
1 month (2020-12-12)	N/A
3 months (2020-10-12)	10.05%
6 months (2020-07-12)	N/A

1 year (2020-01-12)	N/A
2 years (2019-01-12)	N/A
3 years (2018-01-12)	N/A
5 years (2016-01-12)	N/A

Vaccinex financials

Revenue TTM	USD$625,000
Gross profit TTM	USD$324,000
Return on assets TTM	-120.96%
Return on equity TTM	-748.42%
Profit margin	0%
Book value	$-2.295
Market capitalisation	USD$46.6 million

TTM: trailing 12 months

Shorting Vaccinex shares

There are currently 553,693 Vaccinex shares held short by investors – that's known as Vaccinex's "short interest". This figure is 31.3% down from 805,500 last month.

There are a few different ways that this level of interest in shorting Vaccinex shares can be evaluated.

Vaccinex's "short interest ratio" (SIR)

Vaccinex's "short interest ratio" (SIR) is the quantity of Vaccinex shares currently shorted divided by the average quantity of Vaccinex shares traded daily (recently around 1.1 million). Vaccinex's SIR currently stands at 0.52. In other words for every 100,000 Vaccinex shares traded daily on the market, roughly 520 shares are currently held short.

However Vaccinex's short interest can also be evaluated against the total number of Vaccinex shares, or, against the total number of tradable Vaccinex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaccinex's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vaccinex shares in existence, roughly 20 shares are currently held short) or 0.0448% of the tradable shares (for every 100,000 tradable Vaccinex shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaccinex.

Find out more about how you can short Vaccinex stock.

Vaccinex share dividends

We're not expecting Vaccinex to pay a dividend over the next 12 months.

Vaccinex share price volatility

Over the last 12 months, Vaccinex's shares have ranged in value from as little as $1.63 up to $9.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 1.8054. This would suggest that Vaccinex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Vaccinex overview

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

Frequently asked questions

• What percentage of Vaccinex is owned by insiders or institutions?

  Currently 18.395% of Vaccinex shares are held by insiders and 50.284% by institutions.

• How many people work for Vaccinex?

  Latest data suggests 45 work at Vaccinex.

• When does the fiscal year end for Vaccinex?

  Vaccinex's fiscal year ends in December.

• Where is Vaccinex based?

  Vaccinex's address is: 1895 Mount Hope Avenue, Rochester, NY, United States, 14620

• What is Vaccinex's ISIN number?

  Vaccinex's international securities identification number is: US9186401033

• What is Vaccinex's CUSIP number?

  Vaccinex's Committee on Uniform Securities Identification Procedures number is: 918640103